NEW YORK, June 15, 2012 /PRNewswire/ -- ExL Pharma will host the 2nd Pharmaceutical Research Collaborations Summit August 14-15 at the Hyatt Harborside in Boston.
One of the critical questions facing the pharmaceutical industry today is where will future R&D dollars come from. The patent cliff and other forces are making it difficult for large pharmaceutical companies to maintain large-scale internal research departments. As a result, pharmaceutical companies frequently look outside of their company to benefit from discoveries that may be further along the development pipeline, reducing the financial risk of bringing them further.
The two-day program focuses on various strategies pharmaceutical companies take to benefit from outside research. Sessions will highlight case studies on partnerships between large pharmaceutical and biotech companies, universities, small biotechs, and virtual pharma companies. Panelists will discuss the different goals of the different institutions, venture capital opportunities, and intellectual property considerations. Attendees will hear presentations on open innovation case studies, regulatory issues, and the finer points of alliance management.
The diverse speaker staff draws from some of the leading life science research institutions and companies, including MIT, Abbott Ventures, Boston University, Biogen Idec, Tufts, Merck, Millennium, Novartis, Yale, Pfizer, Sanofi, and more. These different points of view will shed light on the dynamics that promise to drive scientific research in coming years.
To find out more information regarding attending the 2nd Pharmaceutical Research Collaborations Summit, please contact Shari Gelfand on email@example.com or visit
|SOURCE ExL Pharma|
Copyright©2012 PR Newswire.
All rights reserved